The Course of AαVal541 as a Proteinase 3 Specific Neo-Epitope after Alpha-1-Antitrypsin Augmentation in Severe Deficient Patients.

Int J Mol Sci · 2021 · PMC8347723 · PMID 34360796

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

showed a trendp = 0.054so close (0.05 < p ≤ 0.1)

The pre-administration baseline AαVal541 level of the AATD patients before they received their first AAT augmentation therapy showed no correlation with baseline pulmonary function, although diffusion capacity (KCO) showed a trend to a negative correlation with baseline AαVal541 level (Spearman’s correlation coefficient—0.624, p = 0.054). 2.4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.